SUMGEN
Latest round
- Series B
Last raised
- Dec 2021
Total raised
- $40M
Investors
- 11
About SUMGEN
, Ltd. trading as SUMGEN, is a biopharmaceutical company dedicated to the creation and commercialization of antibody therapeutics for cancer and other serious diseases. The company develops an integrated process covering drug discovery, manufacturing, and clinical development. The company's main product pipeline is focused on broad immuno-oncology targets, with SG001, SG301, SG404, and SG12473 projects in the clinical study stage. It also offers a technology platform for antibody discovery for bispecific antibodies and deployed abundant innovative pipelines in the tumor field. The company generates revenue by doing R&D, and providing innovative antibody drugs for the treatment of major diseases such as cancer and other related products.
Who invested in SUMGEN
11 investors across 3 rounds
See all investors in SUMGEN
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about SUMGEN
Who invested in SUMGEN?
SUMGEN has 11 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has SUMGEN raised?
SUMGEN has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did SUMGEN last raise money?
SUMGEN's most recent round on record is a Series B, in Dec 2021.
What does SUMGEN do?
SUMGEN is a biotechnology company.
Where is SUMGEN headquartered?
SUMGEN is headquartered in Hangzhou, China.
Which VCs invest in companies like SUMGEN?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at SUMGEN's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like SUMGEN? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.